Houston, United States
Research view
Sarcoma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- KRAS 10
- TP53 1
- PD-1 19
- PD-L1 9
- PI3K 0
- AKT 0
- NTRK 2
- mTOR 0
- STAT3 0
- MAPK 0
- CTNNB1 0
- MDM2 2
- BRAF 3
- MYC 0
- RAS 3
- JNK 0
- VEGF 3
- ERK 0
- ALK 2
- B7-H3 10
- STING 1
- CDK4/6 3
- JAK 1
- PARP 4
- YAP 0
- EGFR 1
- IDH 2
- FGFR 2
- HER2 5
- MEK 2
- CTLA-4 5
- NRAS 0
- HIF-1 0
- PTEN 0
- EZH2 0
- GPX4 0
- PPAR 0
- NF1 5
- AMPK 0
- GPC3 5
- METTL3 1
- PDGFR 3
- ABL1 0
- COX-2 0
- ROS1 2
- AXL 0
- CD47 0
- CDKN2A 0
- IL-15 4
- MMP-9 0
- PRAME 1
- PSMA 0
- RET 0
- BCL-2 0
- BRCA2 1
- CD19 2
- CXCR4 0
- FLT3 0
- FTO 0
- HDAC 0
EU-13 is a filter, not a ranking: it only narrows the list.
Milan, Italy
Philadelphia, United States
Stanford, United States
Toronto, Canada
Boston, United States
Warsaw, Poland
Utrecht, Netherlands
Gainesville, United States
Barcelona, Spain
Mumbai, India
Seattle, United States
Shanghai, China
Lille, France
Madrid, Spain
Rome, Italy
Columbus, United States
Guangzhou, China
Chengdu, China
Miami, United States
Sydney, Australia
Beijing, China
Duarte, United States
Graz, Austria
24 of 33+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
“Limited Accrual”Registry text, quoted unchanged. Source
Suspended
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
“seeking additional funding”Registry text, quoted unchanged. Source
Terminated
A Study of XmAb23104 in People With Sarcoma
“Vendor decided study to be closed early”Registry text, quoted unchanged. Source
Terminated
“Inadequate accrual rate”Registry text, quoted unchanged. Source
Terminated
“Business Decision”Registry text, quoted unchanged. Source
Terminated
“The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.”Registry text, quoted unchanged. Source
Withdrawn
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
“Discontinuation of molecule development”Registry text, quoted unchanged. Source
Terminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
“Study terminated by sponsor”Registry text, quoted unchanged. Source
Withdrawn
“Study never started/ will not proceed.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 40
- Organoids 10
- Mendelian Randomization Analysis 2
- CRISPR-Cas Systems 10
- Gene Expression Profiling 99
- Sequence Analysis, RNA 21
- Whole Genome Sequencing 4
- Exome Sequencing 14
- Proteomics 31
- Metabolomics 7
- Mass Spectrometry 5
- Flow Cytometry 52
- Immunohistochemistry 184
- Liquid Biopsy 12
- Circulating Tumor DNA 19
- Xenograft Model Antitumor Assays 152
- Positron-Emission Tomography 19
- Magnetic Resonance Imaging 194
- Machine Learning 28
- Deep Learning 16
- Cohort Studies 30
- Genome-Wide Association Study 2
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.